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Objectives:Major proteasemutations are rarely observed following first-line failure with PIs and interpretation of
genotyping results in this context may be difficult. We performed extensive phenotyping of viruses from five
patients failing lopinavir/ritonavir monotherapy in the MONARK study without major PI mutations by standard
genotyping.
Methods: Phenotypic susceptibility testing and viral infectivity assessments were performed using a single-cycle
assay and fold changes (FC) relative to a lopinavir-susceptible reference strain were calculated.
Results: .10-fold reduced baseline susceptibility to lopinavir occurred in two of five patients and .5-fold in
another two. Four of five patients exhibited phylogenetic evidence of a limited viral evolution between baseline
and failure, with amino acid changes at drug resistance-associated positions in one: T81A emerged in Gag with
M36I in the protease gene, correlating with a reduction in lopinavir susceptibility from FC 7 (95% CI 6–8.35) to FC
13 (95% CI 8.11–17.8). Reductions in darunavir susceptibility (.5 FC) occurred in three individuals.
Discussion: This study suggests both baseline reduced susceptibility and evolution of resistance could be contrib-
uting factors to PI failure, despite the absence of classical PI resistance mutations by standard testing methods.
Use of phenotyping also reveals lower darunavir susceptibility, warranting further study as this agent is com-
monly used following lopinavir failure.
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Introduction
Global scale-up of antiretroviral therapy is witnessing a transition
of substantial numbers of patients to second-line regimens con-
taining the PI lopinavir coformulated with the booster agent
ritonavir (lopinavir/ritonavir). Given the high prevalence ofmultiple
NRTI mutations at virological failure in resource-limited settings
(conferring cross-resistance to other NRTI),1 – 5 there has been
concern that second-line treatment may result in functional
monotherapy in some individuals. Indeed, rates of virological fail-
ure to PI-based second-line therapies are significant.6–8 In these
settings, lopinavir/ritonavir monotherapy has been explored in
patients failing the WHO-recommended first-line therapy with a
non-NRTI regimen and found to be inferior to triple-drug regimens
containing a PI.9–12
In better-resourced settings, only one trial to date has explored
first-line ritonavir-boosted PI monotherapy (PI/r; in the form of
lopinavir/ritonavir) in antiretroviral-naive patients.13,14 In contrast,
PI/r monotherapy has been explored as a maintenance regimen
in multiple trials as a strategy to reduce cost and risk of toxicity
over the longer term.15–17 The MONARK trial investigated the effi-
cacyof lopinavir/ritonavirmonotherapy in comparisonwith lopinavir/
ritonavir+two NRTIs at treatment initiation in treatment-naive
patients. Higher rates of virological failure were reported in the
monotherapy arm.13,14Of the 23 genotyped patients experiencing
virological failure in the lopinavir/ritonavir monotherapy arm at
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96 weeks, 5 (21.7%) hadmajor PI resistancemutations versus 0/5 of
those genotyped in the triple-therapy arm.18 These data are consist-
ent with a wide literature on virological failure with PI/r, where lower
prevalence ofmajor PI resistancemutations relative to other classes
is generally observed.19,20 An earlier analysis of MONARK exploring
non-protease determinants of failure had reported that pre-therapy
mutations in Gag cleavage site sequences were significantly asso-
ciated with the virological outcome of a first-line lopinavir/ritonavir
single-drug regimen, in spite of the absence of consistent association
with either the emergence of major PI resistance mutations or with
changes in Gag sequences at the time of virological failure.21
Numerous studies have provided evidence for the role of Gag
in PI susceptibility, with amino acid changes located both in and
outside of the Gag cleavage sites (reviewed in Fun et al.22).
Identification of broad genotypic predictors of PI susceptibility
using Gag–protease remains elusive, most probably due to the
importance of coevolution of residues on individual Gag
sequences.23,24 The inclusion of full-length patient-derived Gag
alongside its coevolved protease in in vitro phenotypic assays
has been shown to substantially affect PI susceptibility (as com-
pared with the use of protease sequences alone) in patients not
exposed to PI25,26 and in a heavily treated patient with multiple
major resistance mutations in protease.27 There are no data
using this method for the most relevant clinical application:
assessment of susceptibility to PI following failure of this class
of drug (when major mutations in protease are not detected by
standard population sequencing-based methods).
Given the clinical and public health needs to better understand
virological failure on PI therapy, and the lack of predictive power of
gag– protease genotyping, this study sought to phenotypically
investigate treatment failure using multiple coevolved, full-length
gag –protease sequences from patient plasma at baseline and
time of treatment failure on PI monotherapy. We specifically
wished to determine whether viral failure in the absence of
major PImutations (by population sequencing) was accompanied
by reductions in phenotypic susceptibility to lopinavir and the
other PIs saquinavir, atazanavir and darunavir.
Methods
Amplification of full-length gag–protease from study
participants
Paired baseline and failure samples of the 23 patients experiencing viro-
logical failure whilst on lopinavir/ritonavir drug selective pressure in
MONARK (up to week 96) were available. Full-length gag–protease from
both baseline and failure plasma samples was successfully amplified
from five patients. Reasons for exclusion of the other 18 patients are pre-
sented in Figure 1.
Full-length gag–protease was amplified from patient samples as previ-
ously described.26,28 Clonal sequence analysis of 10 viral variants for each
sample was performed in MEGA 5.0 software using ClustalW. The variant
that most closely represented the consensus for each timepoint was
selected for phenotypic testing, along with other variants of interest.
PI susceptibility testing
PI susceptibility and single-round infectious titre were determined using
previously described single-cycle assays.25,27 In this assay, normalization
by p24 or volume of viral input dose have been shown to be equivalent for
multiple viruses.27,29
Phylogenetics
Sequences were aligned in MEGA 5.0 software30 using the ClustalW algo-
rithm and imported into the PHYLIP program for phylogeny construction
(http://evolution.genetics.washington.edu/phylip.html) using the max-
imum likelihood method under the generalized time reversible (GTR)
model of nucleotide substitution.31 Maximum likelihood trees were con-
structed with the confidence tested using 500 bootstrap replications.
Phylogenetic trees were viewed using FigTree v1.3.1 (http://tree.bio.ed.ac.
uk/software/figtree/) and MEGA 5.0 software.
Mean pairwise genetic distance (MPWGD) calculation
Genetic distance calculation was carried out in MEGA 4.1 using default
parameters, based on amino acid alignments. Data were expressed as
mean amino acid substitutions per site. Differences in MPWGD between
screening and failure were calculated using Student’s t-test (GraphPad
Prism, La Jolla, CA, USA).
Results
Study group characteristics
The samples from five patients underwent sequence analysis as
described in Figure 1. Clinical and virological information for these
five patients including viral load, subtype and time of treatment
failure is shown in Table 1. Patients randomized to the lopinavir/
ritonavir monotherapy arm harboured the following HIV subtypes:
68% B, 16% CRF02_AG, 2% A, 4% G and 10% other subtypes.18
The five patients detailed here were infected with subtypes B
(two patients), CRF02_AG (two patients) and G (one patient), as
determined by the REGA subtyping tool32,33 (http://dbpartners.
stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/). The
patients had a range of viral loads at time of failure (Table 1).
In addition, the five patients experienced virological failure from
week 24 (failure to achieve the primary endpoint of viral load
,400 copies/mL by week 24) to week 96 (the total length of trial
follow-up). Therapy adherence data from compliance assessments
carried out at nine timepoints and lopinavir trough concentrations
measured in the blood plasma at three timepoints were available.
Reduced baseline susceptibility with further reduction
at failure
One individual (Patient 1403) was infected with a subtype
CRF02_AG virus and experienced therapy failure at week 24 with
a viral load at 24000 copies/mL. At this timepoint, very low non-
suppressive lopinavir levels were present in the plasma (75 ng/mL)
and missed doses were reported. Clonal sequence analysis
revealed the presence of the V82A major PI resistance mutation
in 1 of the 10 viral variants isolated from the time of treatment
failure, as well as a number of protease polymorphisms at both
screening and failure (Table S1, available as Supplementary data
at JAC Online). In addition, a number of mutations previously
associated with PI susceptibility or resistance in Gag were present
at both screening and time of treatment failure: E12K, R76K,
T375N, I376V and L449P (Table S2).22 The emergence of Y79F in
failure variant 6 (F6) and F9 correlated with PI exposure.
Phenotypic drug susceptibility and infectivity was tested for
seven variants from Patient 1403: two from the time of screening
(S1 and S5) and five from the time of treatment failure (F2, F5, F6,
F7 and F9). Of note, the F5 variant containing themajor PI resistance
Gag–protease in lopinavir failure
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mutation V82A displayed significantly reduced susceptibility to lopi-
navir (17-fold). For the remaining variants, reduced susceptibility in
comparison with the reference strain was observed to both ataza-
navir and lopinavir [.10-fold change (FC) in EC50] for S1, F2 and F5.
In contrast, F6 and F9 displayed susceptibilities similar to the assay
reference strain to atazanavir and lopinavir, despite emergence of
Y79F (Figure 2a). Susceptibility levels similar to that of the reference
strain were observed for all variants to the PIs darunavir and
saquinavir and use of EC90 instead of EC50 to calculate FCs did not
significantly change the relationships between clones, although
the magnitude of the FCs was reduced (Figure S1). There was little
variation in MPWGD at screening and time of failure (0.007 versus
0.009 nucleotide substitutions per site, P¼0.0765) and screening
and failure viral variantswere phylogenetically distinct bymaximum
likelihood analysis (Figure 3).
The second individual (Patient 3204) was infected with a sub-
type B virus and experienced virological failure at week 40
(Table 1). No lopinavir trough concentration was available at this
timepoint; however, at weeks 4 and 24, lopinavir trough concen-
trations were .3000 ng/mL and no missed doses were reported.
A number of polymorphisms were present in protease at both
screening and failure: E35D, L63P, I72V, V77I and I93L (Table S1).
23 with virological failure on 
lopinavir/ritonavir monotherapy
between weeks 24 and 96 of 
the MONARK trial*
22 patients with plasma sample
available for baseline and
failure timepoints
Patients with major PI resistance
mutations at failure excludeda
(n = 5)
Amplification from failure
sample unsuccessful
(n = 4)
Amplification from failure
sample not attemptedc
(n = 2)
Gag–protease successfully
amplified from plasma sample
at time of treatment failure
(n = 5)
*23/33 were on a lopinavir/ritonavir single-drug regimen at the time of virological failure and the
remaining 10 had discontinued study treatment.
aAs detected by clinical testing during the trial.
bPatients with a subtype present at low frequency in the MONARK trial (A1 and CRF01_AE) or
viral load <200 copies/mL at failure were excluded.
cViral load <200 copies/mL, below limit of detection for our PCR.
Amplification not attemptedb
(n = 4)
Gag–protease amplification
failed (n = 2)
Gag–protease successfully
amplified from screening
sample (n = 11)
PCR to amplify full-length Gag–
protease from screening
plasma sample (n = 13)
Figure 1. Patient sample selection flow diagram.
Table 1. Clinical data on participants
Patient Subtype
Screening viral
load (copies/mL)
Failure
time
(weeks)
Failure viral
load
(copies/mL)
1403 CRF02_AG 44600 24 24000
3204 B 23800 40 603
1404 CRF02_AG 166000 48 212
4201 G 79500 48 342
508 B 37800 96 25300
Sutherland et al.
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In addition, a numberofmutations that have been previously asso-
ciated with PI susceptibility or resistance in Gag were present at
both screening and time of treatment failure: Y79F, T81A, M200I,
H219Q, S373P, T375N, R380K, I389Tand S451N (Table S2). A num-
ber of amino acid positions correlated with PI exposure: 12, 63, 70,
310, 370 and 376 in Gag and 36 in protease (Tables S1 and S2).
T81A was seen in only 1 of 10 screening variants but in all failure
variants. Overall, E12K, T81A and M36I were of greatest interest as
they have been previously associated with PI exposure and
reduced susceptibility.34,35
Seven viral variants were tested phenotypically, five from base-
line (S1, S2, S6, S8 and S9) and two from the time of treatment
failure (F1 and F2). Figure 2(b) shows that screening variants
hadmodestly reduced susceptibility (7 FC) to lopinavir, atazana-
vir and saquinavir. Failure variants displayed lower susceptibilities
to atazanavir, darunavir, lopinavir and saquinavir than the screen-
ing variants. This wasmost pronounced for atazanavir and lopina-
vir, where up to a 16-fold and 13-fold reduction in susceptibility
was observed in comparison with the assay reference strain,
respectively (Figure 2b). Surprisingly, moderately reduced
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Figure 2. Phenotypic PI susceptibility. Phenotypic susceptibility to four PIs atazanavir (ATV), darunavir (DRV), lopinavir (LPV) and saquinavir (SQV) was
determined for viral variants derived from five patients: (a) 1403, (b) 3204, (c) 1404, (d) 4201 and (e) 508. Data are presented as FC in EC50 in comparison
with the assay reference strain. BL, baseline; F, failure.
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susceptibility was also observed for darunavir, of up to 5 FC for the
failure viral variants. Use of EC90 did not significantly change the
relationships between clones (Figure S1). There was a significant
difference in MPWGD between baseline (0.019) and time of treat-
ment failure (0.001, P,0.0001) and phylogeny was consistent
with ongoing evolution and selection during PI therapy (Figure 3).
Reduced baseline phenotypic susceptibility with no
change at failure
Patient 1404was infectedwith subtype CRF02_AG virus and experi-
enced virological failure at week 48 of the trial with a low viral load
of 212 copies/mL. The lopinavir plasma trough concentration was
unavailable for this timepoint, although the lopinavir level at week
24 was ,1000 ng/mL and missed doses were reported at weeks
20, 40 and 48. The minor resistance mutation A71T was present
in protease of viral variants from screening and the time of treat-
ment failure, along with a number of polymorphisms: I13A, K20I,
M36I, R41K, H69K, L89I and I93M (Table S1). In addition, a number
of mutations that have been previously associated with PI suscep-
tibility or resistance in Gagwere present at both screening and time
of treatment failure: E12K, R76K, V370A and L449P (Table S2).
Six viral variants in total were cloned into the resistance test
vector and underwent phenotypic analysis: four from baseline
(S4, S5, S6 and S8) and two from the failure timepoint (F1 and
F4). For this patient, reduced PI susceptibility to atazanavir and
Patient 1404
Patient 1403
Patient 4201
Patient 3204
Patient 508
Subtype K reference
Screening timepoint
Failure timepoint
0.05
*
* *
*
*
*
* *
*
*
*
*
*
*
*
**
** ** *
*
*
* *
*
*
Figure 3. Maximum likelihood phylogeny. Amaximum likelihood tree constructed using the GTRmodel in PhyML using an alignment of all variants from
baseline and failure timepoints from five patients. Variants from each patient are represented by a single colour, the screening variants by triangles and
those from failure with circles. Nodes supported by .75% bootstrapping (≥350/500) are marked by an asterisk (*). This figure appears in colour in the
online version of JAC and in black and white in the print version of JAC.
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lopinavir was observed with the screening variants and F1, with
each displaying similar FC EC50 values of up to 11- and 8-fold
respectively, as shown in Figure 2(c). Screening variants remained
susceptible to darunavir, although variant F4 displayed a 5-fold
reduction in PI susceptibility. Use of EC90 did not significantly
change the relationships between clones (Figure S1). MPWGD was
reduced at the time of treatment failure (0.002) in comparisonwith
baseline (0.009, P,0.0001). Screening and failure viral variants
clustered in a stepwise fashion in a maximum likelihood analysis
(Figure 3), consistent with selective pressure and ongoing viral evo-
lution between the two timepoints.
The second individual (Patient 4201)was infectedwith a subtype
G virus and experienced virological failure atweek 48of the trial. The
patient had a lopinavir trough concentration .6000 ng/mL at this
timepoint, though levels were undetectable at the week 24 visit.
Adherence reporting suggested erratic drug exposure from week
20 onwards. A number of protease polymorphisms were present
both at baseline and time of treatment failure: I13V, K14R, K20I,
E35Q, M36I, R41K, R57K, Q61N, C67E, H69K, V82I and L89M
(Table S1). In addition, a number of mutations that have been pre-
viously associated with PI susceptibility or resistance in Gag were
present at both screening and time of treatment failure: E12K,
R76K, H219Q, V370A, R380K, K436R and S451N (Table S2).
Five variants were subjected to phenotypic analysis: four
derived from baseline (S1, S3, S4 and S5) and one from failure
(F2). The baseline viral variants S1 and S5 displayed significant
reductions in susceptibility to a number of PIs, most notably to
lopinavir where≥16-fold reduction in susceptibility in comparison
with the reference strain was observed (Figure 2d). Reduced sus-
ceptibility to atazanavir (up to 11-fold), darunavir (up to 5-fold)
and saquinavir (up to 4-fold) were also observed. This reduction
in susceptibility was also observed for the viral variant derived
from the failure timepoint, F2. The other variants derived from
the baseline timepoint, S3 and S4, exhibited less pronounced
reductions in susceptibility to lopinavir of 8- and 11-fold, respect-
ively. In contrast to the other patients studied, the FC for Patient
4201 remained .10, even when considering EC90 (Figure S1).
Furthermore, the use of EC90 revealed two screening variants
with.5 FC to darunavir, which were,5-fold when EC50 was con-
sidered. Finally, there was a significant difference in MPWGD
between baseline (0.014) and time of treatment failure (0.001,
P,0.0001). The screening and failure viral variants clustered sep-
arately on the maximum likelihood phylogenetic tree, supporting
ongoing viral evolution during PI monotherapy (Figure 3).
Virological failure with ‘wild-type’ virus after prolonged
suppression
Patient 508 was infected with subtype B and experienced late
therapy failure at week 96 with a viral load at 25300 copies/mL.
Although lopinavir plasma trough concentrations were unavail-
able beyond week 48, those prior to this timepoint were consist-
ently .2000 ng/mL and very few missed doses were reported.
A number of protease polymorphisms were present both at base-
line and time of treatment failure: N37S, P39Q, I62V, L63P, V77I
and I93L. Only one change in Gag associated with PI susceptibility
or resistance was present—V370A (V/A mixture pre-therapy and
all V370A at failure, Tables S1 and S2).
Phenotypic susceptibility was measured for six variants in
total: three each from baseline (S1, S2 and S3) and the time of
treatment failure (F2, F3 and F9). Figure 2(e) shows that for lopi-
navir, most viral variants remained susceptible with up to 4-fold
reduction in susceptibility in comparison with the reference strain.
In addition, viral variants were susceptible to darunavir. Use of
EC90 instead of EC50 did not significantly change the relationships
between clones (Figure S1). MPWGD at baseline (0.011) and time
of treatment failure (0.010, P¼0.07) were not significantly differ-
ent and baseline and failure viral variants intermingled on phylo-
genetic analysis, in contrast to the other patients studied
(Figure 3). This is consistent with a dramatic change in adherence
after a prolonged period of suppression. Of note, bootstrap values
were relatively low for the nodes between the branches within
each patient, likely due to the close relatedness of the variants.
Discussion
The MONARK clinical trial offered the unique opportunity to carry
out themost detailed analysis of PI/rmonotherapy failure to date,
focusing on the most relevant patients failing lopinavir/ritonavir
single-drug first-line treatment: those who do so in the absence
of major PI mutations by bulk population sequencing. Given the
evidence for the importance of the inclusion of full-length gag
alongside its coevolved protease in phenotypic assays, we set
out to examine in this proof-of-concept study whether testing
phenotypic PI susceptibility of multiple full-length gag–protease
sequences from individual patients failing therapy in the absence
of major PI resistance mutations could be more illuminating. The
paired nature of these samples, one taken before treatment and
one at time of treatment failure, enabled a comparison of PI
susceptibility and amino acid sequence of viruses before and
after PI/r monotherapy. Uniquely, we were able to contextualize
our phenotypic data with lopinavir plasma concentrations, adher-
ence and clinical data.
We show using multiple patient-derived gag–protease
sequences that decreases in phenotypic susceptibility can occur
(in two of four failures occurring before 96 weeks) when no major
PI mutations during lopinavir/ritonavir therapy are detected using
standard techniques. Use of multiple clones in phenotypic analysis
enabled us to test lower-frequency variants and this approach was
vindicated by the detection of a protease V82Amajormutation in a
single clone at virological failure in Patient 1403. This viral popula-
tion with reduced lopinavir susceptibility (17-fold for lopinavir)
would have been missed by both consensus sequencing and con-
sensus strain susceptibility testing.Wedetected a second individual
(Patient 3204) with an emergent reduction in PI susceptibility
(13-fold to lopinavir), also ona backgroundof reduced susceptibility
and associated with amino acid changes in Gag and M36I in prote-
ase. M36I has been associated with PI exposure,26,36 though was
not linked to reduced susceptibility in a commercial phenotypic sus-
ceptibility system incorporating only patient-derived protease
sequences.37 The resistance pathway involving M36I could there-
fore involve the Gag positions in Table S2.
The lower and upper clinical cut-offs (CCOs) for lopinavir are 10
and 50, derived using a protease-containing phenotypic assay with
an assay reference strain also derived from NL4.3.38 The CCOs for
lopinavir/ritonavir monotherapy have not been established but
may be lower given that CCOs are derived from clinical studies con-
ducted with triple-agent antiretroviral therapy. In light of these
data, one would not restart lopinavir/ritonavir monotherapy in
Gag–protease in lopinavir failure
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these individuals and atazanavir is probably not an alternative
given the overlapping susceptibility profiles observed both in the
presence39 and absence of major protease mutations.25,26
An alternative to restarting the same PI in resource-limited set-
tings might be a switch to a darunavir/ritonavir-based third-line
regimen. However, this study has revealed a possible compromise
of darunavir activity in three of five individuals with virological fail-
ure. In Patient 4201, there was an FC of 5 relative to the reference
strain both before and after virological failure. Comparable levels
of reduction in darunavir susceptibility were previously seen in
only 1 of 15 treatment-naive isolates tested using this assay (9
subtype B,26 3 subtype A and 3 subtype C25). Reduced darunavir
susceptibility of 5-fold emerged at failure in Patients 3204 and
1404, having been significantly lower pre-therapy (Figure 2).
Although the darunavir CCO has been set at 10-fold (in a commer-
cial protease-only vector system), this might be too high in set-
tings of darunavir monotherapy or functional monotherapy.
Further studies are needed to properly define CCOs in the context
of a gag–protease phenotypic assay and also for PI monotherapy.
Notably, the darunavir susceptibility score is based around prote-
ase mutations (as are all scoring systems) and would not have
detected the reduced susceptibility observed in our study.
Therefore, our approach, if validated by larger studies, could
potentially be used to assess patients for darunavir/ritonavir-
based salvage therapy.
Finally, our work has demonstrated some degree of reduced
baseline susceptibility (.5-fold to any PI) in all five patients.
Data for one patient in particular, Patient 4201, provided evidence
that a significant reduction in PI susceptibility at baseline may
contribute to treatment failure. The baseline variants for this
patient displayed up to 16-fold reduction in susceptibility to lopi-
navir (using both EC50 and EC90) that was also present at treat-
ment failure. This degree of reduction in PI susceptibility was
the same as observed for variant 1403 F6, which contained the
V82A major PI resistance mutation, implying clinical relevance
in the FCs observed for gag-associated mutations. Patient 4201
failed at week 48 of the clinical trial, at which time an adequate
lopinavir trough plasma concentration was present and self-
reported adherence was high at most appointments. This indi-
cates that the reduced PI susceptibility may have enabled viral
replication in the presence of PI/r monotherapy. We hypothesize
that the reduced PI susceptibility present in baseline viral variants
reduces the therapeutic forgiveness of suboptimal adherence,
thus rendering these patients more likely to experience virological
failure.
Of note, our findings are in patients treated with lopinavir/
ritonavir monotherapy and therefore may not be generalizable
to triple-therapy regimens containing this PI. Furthermore, treat-
ment guidelines now specify that boosted lopinavir or darunavir
should only be used as monotherapy following viral suppression
with a triple combination regimen (http://www.eacsociety.org/
Portals/0/140601_EACS%20EN7.02.pdf). The characteristics of
emerging virus populations following maintenance may not be
the same as those observed in our analysis. A final consideration
relates to data from both MONET and OK04 demonstrating suc-
cessful resuppression with the addition of two nucleosides follow-
ing viral rebound on maintenance with PI monotherapy.16,17 In
the latter, resistance testing was undertaken and two nucleosides
only reintroduced if there was no genotypic evidence of lopinavir
resistance.16 It is still possible that the period of suppression under
maintenance strategies will differentially impact the nature of
emerging virus at rebound. Our approach should therefore be
repeated using samples from maintenance studies in the future.
Several limitations to this study deserve mention. We have
used a bulk PCR approach that can be prone to recombination.
The alternative, single genome amplification, could be biased by
the fact that one would need to select ‘representative’ sequences
from.30 sequences for phenotyping. Secondly, the sample size is
relatively small, despite the intensive clonal analyses at baseline
and failure for each patient. Thirdly, our vector system does not
incorporate native envelope, proposed as being a determinant
of PI susceptibility whilst this manuscript was in preparation.40
Finally, use of a single reference strain may be a limitation,
although all viruses were compared with the same reference
strain in this study as in previous publications.25–27 Future studies
will be needed to establish the utility of coevolved gag–pro–env in
the assessment of drug susceptibility in clinical isolates and to fur-
ther address differential susceptibility to PI in determining clinical
outcomes.
Conclusions
This study represents the most comprehensive assessment of PI
susceptibility to date. It highlights the complex nature of viro-
logical failure to this class of antiretroviral, suggesting baseline
reduced susceptibility, evolution of resistance or a mixture of
both can be contributing factors. Use of a phenotyping approach
also reveals lower darunavir susceptibility, warranting further
study as this agent is commonly used following lopinavir failure.
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